TY - JOUR T1 - Frequency of Symptomatic Adverse Events in Rheumatoid Arthritis: An Exploratory Online Survey JF - The Journal of Rheumatology JO - J Rheumatol SP - 998 LP - 1005 DO - 10.3899/jrheum.210688 VL - 49 IS - 9 AU - Glen S. Hazlewood AU - Orit Schieir AU - Vivian Bykerk AU - Kamso Mujaab AU - Peter Tugwell AU - George Wells AU - Dawn Richards AU - Laurie Proulx AU - Pauline M. Hull AU - Susan J. Bartlett Y1 - 2022/09/01 UR - http://www.jrheum.org/content/49/9/998.abstract N2 - Objective To generate initial data on the frequency and effect of symptomatic adverse events (AEs) associated with rheumatoid arthritis (RA) drug therapy from the patient perspective.Methods We conducted an exploratory online survey asking patients with RA to indicate whether they currently or had ever experienced the 80 different symptomatic AEs included in the Patient-Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Results were summarized to report their frequency, and regression models were used to estimate their associations with RA medication use and overall bother.Results The 560 patients who completed the survey and reported taking ≥ 1 RA medication (disease-modifying antirheumatic drugs [DMARDs], steroids, nonsteroidal antiinflammatory drugs [NSAIDs]), had a mean disease duration of 8 years, and were on a wide range of DMARDs. The number of symptomatic AEs experienced in the past 7 days was none (6%), 1–10 (28%), 11–20 (28%), and > 20 (38%). Overall, most participants reported that side effects bothered them somewhat (28%), quite a bit (24%), or very much (15%). In multivariable regression analyses, current prednisone and NSAID use were associated with the greatest number of current side effects (26 and 22, respectively). Many of the strongest associations between current symptomatic AEs and medication use aligned with known side effect profiles.Conclusion In this exploratory online survey, patients with RA reported frequent symptomatic AEs with their medications that are bothersome. Further work is needed to develop and validate a measure for use in patients with rheumatic disease. ER -